Skip to main content
PCI Biotech Holding logo

PCI Biotech Holding — Investor Relations & Filings

Ticker · PCIB ISIN · NO0010405640 LEI · 5967007LIEEXZXFIGG77 OL Manufacturing
Open in API
Filings indexed 752 across all filing types
Latest filing 2014-01-30 Regulatory Filings
Country NO Norway
Listing OL PCIB

About PCI Biotech Holding

https://www.pcibiotech.no/

PCI Biotech Holding is a biopharmaceutical company developing therapeutic products based on its proprietary Photochemical Internalization (PCI) technology. This platform is a drug and nucleic acid delivery system designed to enhance the intracellular delivery of therapeutic molecules. The company's development programs are focused on applications in immunotherapy, dermatology, and bioprocessing for the manufacturing of viral vectors. A primary therapeutic area for the technology is cancer, where it aims to improve the efficacy of novel and existing treatments.

Recent filings

Filing Released Lang Actions
PCI Biotech innvilget NOK 12,5 millioner fra Norges Forskningsråd til videreutvikling av PCI for vaksinering
Regulatory Filings Classification · 100% confidence The document is a press release dated January 30, 2014, announcing that PCI Biotech has been granted NOK 12.5 million in funding from the Research Council of Norway for a project related to their PCI technology for vaccine enhancement. This announcement details a specific corporate event related to financing/funding for a project, rather than a full financial report (10-K, IR), a management change (MANG), or a dividend announcement (DIV). It fits best under 'Capital/Financing Update' (CAP) as it concerns securing significant grant funding which impacts the company's resources and project pipeline. It is not a general regulatory filing (RNS) because it is specific to financing/grants.
2014-01-30 Norwegian
PCI Biotech awarded NOK 12.5 million from The Research Council of Norway to further development of PCI for use in vaccination
Regulatory Filings Classification · 100% confidence The document announces that PCI Biotech has been awarded a NOK 12.5 million grant from The Research Council of Norway for a specific project related to their technology. This is a specific corporate event announcement concerning funding/financing for development, rather than a full financial report (10-K, IR), an earnings release (ER), or a management discussion (MDA). It directly relates to capital/financing activities, specifically receiving a grant which impacts the company's financial standing and future development plans. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length is short, but it is the primary announcement itself, not an announcement *about* another report.
2014-01-30 English
PCI Biotech: Successful completion of the first group in the intra-tumour light dose escalation part of the ENHANCE study
Regulatory Filings Classification · 96% confidence The document is a short press release dated January 24, 2014, announcing the successful completion of the first group in a clinical trial (ENHANCE study) for PCI Biotech. It details preliminary results (safety and tumor response) and the recommendation from the Dose Review Committee to escalate the dose. This type of announcement, focusing on operational updates, clinical trial progress, and immediate results, is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is not a full financial report (10-K, IR), a management discussion (MDA), or a formal dividend/capital change notice, and it is an announcement of operational progress, it fits best under the general 'Regulatory Filings' category (RNS) as a specific operational update that doesn't fit the other specialized codes. Given the short length and the nature of reporting a specific operational milestone, RNS is the most appropriate fallback, although ER might sometimes cover such operational highlights if they are tied to a reporting period. However, RNS covers general regulatory announcements not covered elsewhere.
2014-01-24 English
PCI Biotech: Vellykket fullføring av første dosegruppe i den intra-tumor lys-dose eskalerende delen av ENHANCE studien
Legal Proceedings Report Classification · 99% confidence The document is a short press release dated January 24, 2014, announcing the successful completion of the first dose cohort in a clinical study (ENHANCE study) for PCI Biotech. It details preliminary results, committee recommendations, and provides company background. This type of announcement, which reports on operational progress (clinical trial milestones) and is not a comprehensive financial report (like 10-K or IR), nor a formal dividend/share change notice, typically falls under general regulatory announcements or investor relations updates. Given the options, it is a specific operational update that doesn't fit the defined financial/governance codes. Since it is a formal announcement required under securities law ('Denne opplysningen er informasjonspliktig etter verdipapirhandelloven §5-12'), and it is not a specific report type (like ER, IR, or CT), the most appropriate fallback category for a general regulatory disclosure that isn't explicitly covered elsewhere is Regulatory Filings (RNS). It is too detailed to be a simple Report Publication Announcement (RPA) as it contains substantive news, not just a notice about another report.
2014-01-24 Norwegian
PCI Biotech Q4 2010 report.pdf (Att: 275492)
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive financial report for PCI Biotech Holding ASA covering the fourth quarter and the full year of 2010. It includes detailed operational reviews, financial statements (Profit and Loss, Balance Sheet, Changes in Shareholders Equity), and management commentary. Since it covers a period shorter than a full fiscal year (Q4) and provides substantive financial data and analysis, it is classified as an Interim/Quarterly Report. Q4 2010
2011-02-08 English
PCI Biotech Q4 2010 presentation.pdf (Att: 275492)
Investor Presentation Classification · 90% confidence The document is a slide presentation titled “Fourth Quarter and Preliminary 2010 Results” by the CEO and CFO, containing forward-looking statements disclaimers, clinical pipeline updates, financial key figures, and strategic commentary. It is clearly a presentation prepared for investors rather than a formal annual report or regulatory filing. Therefore, it is classified as an Investor Presentation (IP).
2011-02-08 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.